ALNYLAM PHARMACEUTICALS, INC.

Pioneering RNAi gene-silencing therapies for rare genetic and cardiometabolic diseases.

ALNY | US

Overview

Corporate Details

ISIN(s):: US72703U1025 (+1 more)
LEI:
Country:: United States of America
Address:: 675 WEST KENDALL STREET, 2142 CAMBRIDGE
Website:: https://www.alnylam.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company pioneering the development and commercialization of RNA interference (RNAi) therapeutics. This novel class of medicines utilizes a natural biological process to silence specific genes, thereby preventing the production of proteins that cause or contribute to human disease. The company's portfolio of approved medicines targets a range of rare genetic, cardiometabolic, and hepatic infectious diseases, with key products including ONPATTRO®, AMVUTTRA®, GIVLAARI®, and OXLUMO®. Alnylam continues to advance a robust clinical pipeline to address diseases with high unmet medical need, solidifying its leadership in translating RNAi science into transformative treatments for patients globally.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all ALNYLAM PHARMACEUTICALS, INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for ALNYLAM PHARMACEUTICALS, INC.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for ALNYLAM PHARMACEUTICALS, INC. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
OnKure Therapeutics, Inc. Developing less toxic, tumor-agnostic kinase inhibitors for precision cancer therapy.	United States of America	OKUR
ONO PHARMACEUTICAL CO., LTD. Develops innovative medicines for high unmet needs in oncology, immunology, and neurology.	Japan	4528
OPKO Health Inc. Provides clinical diagnostics & develops novel therapies for serious & pediatric diseases.	Israel	OPK
OPKO HEALTH, INC. A biopharma and diagnostics firm offering novel therapies and full-service clinical lab testing.	United States of America	OPK
Opthea Ltd Biopharma that discontinued its wet AMD therapy after its lead drug failed Phase 3 trials.	United States of America	OPT
OPTUS Pharmaceutical Co., Ltd. Develops and manufactures ophthalmic solutions for dry eye, infections, and inflammation.	South Korea	131030
Opus Genetics, Inc. Developing gene therapies for inherited retinal diseases and other blinding conditions.	United States of America	IRD
ORAGENICS INC Biotech developing intranasal drugs for concussion and other brain disorders.	United States of America	OGEN
Oramed Pharmaceuticals Inc. Develops oral drug delivery systems to turn injectable drugs, like insulin, into oral therapies.	Israel	ORMP
ORAMED PHARMACEUTICALS INC. Develops oral drug delivery systems to convert injectable drugs, like insulin, into capsules.	United States of America	ORMP